Axcella Health Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AXLA Nasdaq 8731 https://axcellatx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Axcella Health Inc

Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - Mar 30th, 2023 12:00 pm
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue - Feb 15th, 2023 9:10 pm
Axcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma Conference - Feb 9th, 2023 9:45 pm
Biotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & More - Jan 25th, 2023 3:53 pm
With lean staff, low cash, Axcella races ahead with Long Covid drug - Jan 25th, 2023 10:34 am
Benzinga's Talk of the Town: Top Social Trending Stories You Need To Know - Jan 24th, 2023 2:50 pm
Why Are Axcella Health Shares Gaining Today? - Jan 24th, 2023 11:43 am
Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue - Jan 23rd, 2023 9:15 pm
Axcella Therapeutics Puts Development Of NASH Program Aside, Reduces Workforce By 85% - Dec 15th, 2022 1:04 pm
Axcella Announces Program Reprioritization and Corporate Restructuring - Dec 15th, 2022 1:01 am
Great news for Axcella Health Inc. (NASDAQ:AXLA): Insiders acquired stock in large numbers last year - Dec 8th, 2022 3:00 pm
Axcella Health Inc. (AXLA) Loses 47.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nov 11th, 2022 2:35 pm
Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting - Nov 3rd, 2022 1:59 pm
Axcella Reports Third Quarter Financial Results and Provides Business Update - Nov 1st, 2022 11:00 am
Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022 - Oct 27th, 2022 12:30 pm
Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference - Oct 14th, 2022 5:24 pm
Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members - Oct 13th, 2022 12:00 pm
Axcella Shares Jump Despite Mixed Bag Data From Mid-Stage NASH Trial - Sep 29th, 2022 1:17 pm
Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH) - Sep 29th, 2022 10:00 am
Institutions profited after Axcella Health Inc.'s (NASDAQ:AXLA) market cap rose US$35m last week butprivate equity firms profited the most - Sep 17th, 2022 12:40 pm